UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market

May 15, 2018

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercializing antibiotics in the US, announced on 5/15/18 the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S. The license agreement provides UTILITY with exclusive access to LEO Pharma’s complete dataset for both products, for the purpose of gaining approval of the products in the US.

Mark Beards, CEO of UTILITY, stated: “Both mecillinam and its oral prodrug, pivmecillinam, have proven their worth over decades of use in the clinic for the treatment of Gram-negative infections. They are the most commonly used systemic antibiotics in certain markets for urinary tract infections, and continue to demonstrate low resistance and high success rates based on real world evidence. On this basis, we are confident that the introduction of these products in the US can offer a new and important treatment option for patients as well as an opportunity reduce dependence on last resort antibiotics.”

The financial terms of the licence agreement are not being disclosed. UTILITY intends to apply to the U.S. Food and Drug Administration (FDA) for designation of both mecillinam (injectable) and pivmecillinam (oral prodrug) as Qualified Infectious Disease Products (QIDP) for the indication of complicated urinary tract infections (cUTI).
UTILITY was formed specifically to hold the exclusive US rights to mecillinam and pivmecillinam licensed from LEO Pharma A/S, and to bring these antibiotics to the US market. It was founded by biotech serial entrepreneurs Dr. Rasmus Toft-Kehler and Dr. Morten Sommer.




CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.